Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05698810
Other study ID # 38RC22.0130
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 20, 2023
Est. completion date March 20, 2033

Study information

Verified date May 2023
Source University Hospital, Grenoble
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Feasibility study: the examinations carried out as part of this protocol aim to carry out all the acquisitions and simulations of use, necessary for the development of the clinical research protocols to come to Clinatec (in particular, configuration of the equipment, dimension of the examination time and the size of the cohorts etc ...)


Description:

To ensure the feasibility of a clinical trial, it is necessary to test the parameters as well as the sequence of the different examination times offered to participants. The expected results of this protocol are mainly the dimension of experimental paradigms and the optimization of the clinical management of subjects.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date March 20, 2033
Est. primary completion date March 20, 2033
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age ? 18 years - Affiliated to a social security scheme - Free and informed consent signed Exclusion Criteria: - Subject in a period of exclusion from another study. - Subject deprived of liberty by a judicial or administrative decision, or major subject subject to a legal protection measure (guardianship, curatorship and safeguarding of justice) referred to in Articles 1121-6 to 1121-8 of the Public Health Code. - Subject who would receive more than 4500 euros in compensation because of his participation in other research involving the human person in the 12 months preceding this study. - Pregnant woman, parturient, nursing mother (Article 1121-5 of the Public Health Code) - Subject not reachable urgently.

Study Design


Intervention

Other:
CE marked Medical Device MagnetoEncephaloGraphy (MEG) usability
tests
CE marked Medical Device Magnetic Resonance Imaging (MRI) usability
tests
CE marked Medical Device ElectroEncephaloGraphy (EEG) usability
tests
CE marked Medical Device ElectroCardioGraphy (ECG) usability
tests

Locations

Country Name City State
France Clinatec Cea/Chuga Grenoble

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Grenoble Commissariat A L'energie Atomique

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary MEG physiological parameters measurements that will be used in future clinical research protocols Adequacy of MEG physiological parameters measurements to the needs of the protocol and duration of the paradigm consistent with the cooperation of the subject through study completion, an average of 10 years
Primary MRI physiological parameters measurements that will be used in future clinical research Adequacy of MRI physiological parameters measurements to the needs of the protocol and duration of the paradigm consistent with the cooperation of the subject through study completion, an average of 10 years
Primary EEG physiological parameters measurements that will be used in future clinical research Adequacy of EEG physiological parameters measurements to the needs of the protocol and duration of the paradigm consistent with the cooperation of the subject through study completion, an average of 10 years
Primary ECG physiological parameters measurements that will be used in future clinical research Adequacy of ECG physiological parameters measurements to the needs of the protocol and duration of the paradigm consistent with the cooperation of the subject through study completion, an average of 10 years
Secondary MEG physiological parameters data collection paradigms Achieving MEG physiological parameters data collection paradigms through study completion, an average of 10 years
Secondary MRI physiological parameters data collection paradigms Achieving MRI physiological parameters data collection paradigms through study completion, an average of 10 years
Secondary EEG physiological parameters data collection paradigms Achieving EEG physiological parameters data collection paradigms through study completion, an average of 10 years
Secondary ECG physiological parameters data collection paradigms Achieving ECG physiological parameters data collection paradigms through study completion, an average of 10 years
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1